Psyched Wellness - CEO and Director, Jeff Stevens.
CEO and Director, Jeff Stevens.
Source: Twitter.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) is reporting positive results from its oral toxicity preclinical study of AME-1, its proprietary Amanita Muscaria extract
  • The study determined that AME-1 posed no treatment-related adverse effects on animals in several key measures when administered daily over 14 days
  • The company’s next step is a preclinical 90-day oral toxicity study to further identify a safe, effective dose for human consumption
  • Psyched Wellness is a health supplements company that distributes mushroom-derived products and associated consumer packaged goods
  • Psyched Wellness (PSYC) is unchanged trading at $0.24 per share

Psyched Wellness (PSYC) is reporting positive results from its oral toxicity preclinical study of AME-1, its proprietary Amanita Muscaria extract.

The study – conducted by KGK Science, a licensed CRO in Canada – determined that AME-1 posed no treatment-related adverse effects on animals in several key measures when administered once daily for 14 days.

Measured indicators include body weight and normal body weight gain, feed consumption, hematology parameters, coagulation, clinical chemistry, gross necropsy and organ weights. 

The company’s next step is a preclinical 90-day oral toxicity study to further identify a safe, effective dose for human consumption.

“This is a major milestone for Psyched Wellness in the development of its Amanita Muscaria-derived products, which will help with promoting stress relief, relaxation and assisting with restful sleeping,” said Brian Tancowny, Scientific Advisor at Psyched Wellness. “The 14-day and 90-day toxicological assessments of AME-1 will importantly form the foundation for all of our future preclinical studies.”

Jeff Stevens, CEO of Psyched Wellness, added,

“Our scientific team is doing a great job executing on the individual studies that make up our preclinical trials. I am pleased to share the positive results of our 14-day toxicity study and look forward to communicating the results from our previously announced 90-day toxicity study when available.”

Psyched Wellness is a health supplements company that distributes mushroom-derived products and associated consumer packaged goods.

Psyched Wellness (PSYC) is unchanged trading at $0.24 per share as of 2:44 pm ET.

More From The Market Herald

" Optimi Health (CSE:OPTI) signs psilocybin supply agreement with Halucenex Life Sciences

Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.